OrbusNeich Medical Group Holdings Limited (HK:6929)
:6929
Want to see HK:6929 full AI Analyst Report?
Top Page
OrbusNeich Medical Group Holdings Limited
(6929)
Select Model
Select Model
Rating:77Outperform
Price Target:
HK$5.00
▲(12.61% Upside)
Action:Reiterated
Date:05/23/26
The score is driven mainly by strong financial positioning (especially the very conservative balance sheet) and an attractive valuation. These positives are partially tempered by weaker recent cash generation (low/declining free cash flow) and only neutral technical momentum.
Positive Factors
Conservative Balance Sheet
Extremely low leverage and a large equity base provide durable financial flexibility. This conservatism supports R&D and commercial investment, cushions cyclical procedure downturns, and enables opportunistic M&A or capital returns without risking solvency over the medium term.
Negative Factors
Weak Cash Conversion
Material deterioration in free cash flow limits internal funding for capex, R&D, or shareholder returns. Persistent weak cash conversion increases reliance on the balance sheet to fund growth and makes the business more vulnerable if operating profits swing or working capital remains elevated.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Extremely low leverage and a large equity base provide durable financial flexibility. This conservatism supports R&D and commercial investment, cushions cyclical procedure downturns, and enables opportunistic M&A or capital returns without risking solvency over the medium term.
Read all positive factors
OrbusNeich Medical Group Holdings Limited (6929) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.20B
Dividend Yield2.7%
Average Volume (3M)176.23K
Price to Earnings (P/E)9.8
Beta (1Y)0.68
Revenue Growth9.88%
EPS Growth5.65%
CountryHK
Employees1,331
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.05
Shares Outstanding827,968,300
10 Day Avg. Volume244,250
30 Day Avg. Volume176,233
Financial Highlights & Ratios
PEG Ratio1.57
Price to Book (P/B)0.93
Price to Sales (P/S)2.13
P/FCF Ratio333.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.05
Revenue Forecast (FY)HK$198.86M
OrbusNeich Medical Group Holdings Limited Business Overview & Revenue Model
Company Description
OrbusNeich Medical Group Holdings Limited functions as an investment holding entity, specializing in the development, distribution, sales, and marketing of medical instruments tailored for treating coronary and peripheral vascular ailments. The co...
How the Company Makes Money
OrbusNeich makes money primarily by selling interventional cardiovascular medical devices used in coronary procedures. Its core revenue stream is product sales to hospitals and healthcare providers (often via catheterization labs), with pricing an...
OrbusNeich Medical Group Holdings Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
54
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 180.45M | 164.10M | 153.87M | 136.82M | 116.46M |
| Gross Profit | 122.43M | 114.47M | 106.50M | 92.46M | 81.17M |
| EBITDA | 42.78M | 36.76M | 53.97M | 27.14M | 8.31M |
| Net Income | 41.90M | 39.72M | 45.07M | 18.49M | -4.44M |
Balance Sheet | |||||
| Total Assets | 452.85M | 431.01M | 410.14M | 351.06M | 268.53M |
| Cash, Cash Equivalents and Short-Term Investments | 218.68M | 248.59M | 256.21M | 247.94M | 175.89M |
| Total Debt | 3.91M | 4.20M | 7.46M | 4.03M | 67.69M |
| Total Liabilities | 38.71M | 36.63M | 40.73M | 28.49M | 85.42M |
| Stockholders Equity | 413.00M | 393.31M | 368.40M | 322.57M | 183.11M |
Cash Flow | |||||
| Free Cash Flow | 1.15M | 1.84M | 15.55M | 20.10M | 18.36M |
| Operating Cash Flow | 19.53M | 13.11M | 23.03M | 23.43M | 20.50M |
| Investing Cash Flow | 15.90M | 8.65M | -52.31M | -169.32M | -5.22M |
| Financing Cash Flow | -29.35M | -18.96M | 884.00K | 57.44M | 146.31M |
OrbusNeich Medical Group Holdings Limited Technical Analysis
Negative
4.44
Price Trends
3.98
Negative
3.79
Positive
3.91
Negative
Market Momentum
-0.02
Positive
43.73
Neutral
48.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6929, the sentiment is Negative. The current price of 4.44 is above the 20-day moving average (MA) of 4.00, above the 50-day MA of 3.98, and above the 200-day MA of 3.91, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.73 is Neutral, neither overbought nor oversold. The STOCH value of 48.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6929.
OrbusNeich Medical Group Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$3.20B | 9.76 | 10.20% | 2.70% | 9.88% | 5.65% | |
77 Outperform | HK$5.46B | 9.29 | 16.76% | 3.65% | 11.07% | 48.01% | |
69 Neutral | HK$6.48B | 21.99 | 11.30% | ― | 25.24% | 7.29% | |
67 Neutral | HK$1.63B | 15.58 | 3.68% | 7.46% | 7.11% | -34.66% | |
66 Neutral | HK$11.45B | 70.86 | 4.01% | ― | ― | ― | |
62 Neutral | HK$14.02B | 7.68 | 6.64% | 4.58% | 2.34% | -22.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6929
OrbusNeich Medical Group Holdings Limited
3.89
0.15
3.87%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.10
-2.78
-47.24%
HK:1358
PW Medtech Group Ltd.
1.13
-0.10
-8.06%
HK:3600
Modern Dental Group Limited
5.85
1.78
43.73%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
30.68
5.93
23.94%
HK:6699
Angelalign Technology Inc.
67.00
14.52
27.67%
OrbusNeich Medical Group Holdings Limited Corporate Events
OrbusNeich Sets 2026 AGM to Approve Dividend, Board Mandates and Share Issuance Flexibility
Apr 13, 2026
OrbusNeich Medical Group Holdings Limited has called its annual general meeting for June 8, 2026, in Hong Kong, where shareholders will review the audited financial statements for the year ended December 31, 2025, and receive reports from the boar...
OrbusNeich Delivers Higher 2025 Profit and Boosts Dividend Despite Margin Pressure
Mar 12, 2026
OrbusNeich Medical Group Holdings Limited reported a 10.0% year-on-year increase in revenue to US$180.5 million for the year ended December 31, 2025, with gross profit rising 7.0% to US$122.4 million despite some margin compression. Net profit att...
OrbusNeich Declares HKD 0.12 Final Dividend for 2025 Financial Year
Mar 12, 2026
OrbusNeich Medical Group Holdings has proposed a final ordinary cash dividend of HKD 0.12 per share for the financial year ended 31 December 2025, underscoring its intention to return capital to shareholders. The distribution, subject to sharehold...
OrbusNeich Sets March 12 Board Meeting to Approve 2025 Annual Results and Consider Final Dividend
Mar 2, 2026
OrbusNeich Medical Group Holdings Limited has scheduled a board meeting for March 12, 2026 to review and approve the annual results for the year ended December 31, 2025, and to consider the publication of those results. The board will also deliber...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.